Home > > > > > Report Detail

Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated skin and soft tissue infections (cSSTI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Complicated skin and soft tissue infections (cSSTI) Understanding

Complicated skin and soft tissue infections (cSSTI): Overview

Skin and soft tissue infections (SSTIs) refer to a wide clinical spectrum of common infectious diseases that often require acute treatment and inpatient hospital admission. Complicated SSTIs (cSSTIs) are the most severe, involving deeper soft tissues and include infective cellulitis, ulcer or wound site infections, surgical site infections, major abscesses, infected burns, skin ulcers, and diabetic foot ulcers. Staphylococcus aureus is the commonest cause of cSSTIs. The management of cSSTIs normally involves a combination of surgical procedures and antibiotic therapy. The main choice of antibiotic depends on the clinical presentation.

"Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complicated skin and soft tissue infections (cSSTI) pipeline landscape is provided which includes the disease overview and Complicated skin and soft tissue infections (cSSTI) treatment guidelines. The assessment part of the report embraces, in depth Complicated skin and soft tissue infections (cSSTI) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complicated skin and soft tissue infections (cSSTI) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Complicated skin and soft tissue infections (cSSTI) R&D. The therapies under development are focused on novel approaches to treat/improve Complicated skin and soft tissue infections (cSSTI).

Complicated skin and soft tissue infections (cSSTI) Emerging Drugs Chapters

This segment of the Complicated skin and soft tissue infections (cSSTI) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Complicated skin and soft tissue infections (cSSTI) Emerging Drugs

- Contezolid (MRX-I): MicuRx Pharmaceuticals Inc.

Contezolid is an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), while offering physicians and patients a safer and better tolerated therapeutic option than currently available oxazolidinone agents. The development of contezolid in China has been designated as a "Significant New Drugs Development Special Project," and contezolid has also been granted QIDP designation and Fast Track status by the US FDA. The drug is in preregistration phase for treatment of cSSTI.

- Ceftobiprole medocaril: Basilea Pharmaceutica

Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp.3 The drug is currently approved and marketed in major European countries, Argentina, Canada, Jordan, Peru and Saudi Arabia for the treatment of adult patients with community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).3 Basilea has entered into license and distribution agreements for the brand in Europe, Latin America, China, Canada, Israel, and the Middle East and North Africa (MENA) region. Ceftobiprole is currently in phase 3 clinical development for a potential registration in the U.S., with a completed study in acute bacterial skin and skin structure infections (ABSSSI) and an ongoing study in Staphylococcus aureus bacteremia (SAB).

Further product details are provided in the report……..

Complicated skin and soft tissue infections (cSSTI): Therapeutic Assessment

This segment of the report provides insights about the different Complicated skin and soft tissue infections (cSSTI) drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Complicated skin and soft tissue infections (cSSTI)

There are approx. 5+ key companies which are developing the therapies for Complicated skin and soft tissue infections (cSSTI). The companies which have their Complicated skin and soft tissue infections (cSSTI) drug candidates in the mid to advanced stage, i.e. phase III include, Baselia pharmaceutica and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

- Late-stage products (phase III)

- Mid-stage products (Phase II and Phase I/II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Complicated skin and soft tissue infections (cSSTI) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Subcutaneous

- Intravenous

- Oral

- Intramuscular

- Molecule Type

Products have been categorized under various Molecule types such as

- Small molecules

- Natural metabolites

- Monoclonal antibodies

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Complicated skin and soft tissue infections (cSSTI): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complicated skin and soft tissue infections (cSSTI) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complicated skin and soft tissue infections (cSSTI) drugs.

Complicated skin and soft tissue infections (cSSTI) Report Insights

- Complicated skin and soft tissue infections (cSSTI) Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Complicated skin and soft tissue infections (cSSTI) Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Complicated skin and soft tissue infections (cSSTI) drugs?

- How many Complicated skin and soft tissue infections (cSSTI) drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complicated skin and soft tissue infections (cSSTI)?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complicated skin and soft tissue infections (cSSTI) therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Complicated skin and soft tissue infections (cSSTI) and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- MicuRx Pharmaceuticals Inc.

- Basilea pharmaceutica

Key Products

- MRX-I

- Ceftobiprole medocaril

Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Complicated skin and soft tissue infections (cSSTI): Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Complicated skin and soft tissue infections (cSSTI) - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Complicated skin and soft tissue infections (cSSTI) companies' collaborations, Licensing, Acquisition -Deal Value Trends
Complicated skin and soft tissue infections (cSSTI) Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Ceftobiprole medocaril: Basilea pharmaceutica
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Complicated skin and soft tissue infections (cSSTI) Key Companies
Complicated skin and soft tissue infections (cSSTI) Key Products
Complicated skin and soft tissue infections (cSSTI)- Unmet Needs
Complicated skin and soft tissue infections (cSSTI)- Market Drivers and Barriers
Complicated skin and soft tissue infections (cSSTI)- Future Perspectives and Conclusion
Complicated skin and soft tissue infections (cSSTI) Analyst Views
Complicated skin and soft tissue infections (cSSTI) Key Companies
Appendix

List of Tables

Table 1 Total Products for Complicated skin and soft tissue infections (cSSTI)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Complicated skin and soft tissue infections (cSSTI)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Cephalosporin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 109
    Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from The fungus Acremonium, which was previously known as "Cephalosporium". The global Cephalosporin market was valued at US$ 1380.7 million in 2023 and is anticipated to reach US$ 1346.9 million by 2030, witnessing a CAGR of -0.3% during The forecast period 2024-2030. Market competition is intense. Qilu Antibiotics, Nectar Lifes......
  • Global Polymixin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 120
    According to our LPI (LP Information) latest study, the global Polymixin market size was valued at US$ 229.9 million in 2023. With growing demand in downstream market, the Polymixin is forecast to a readjusted size of US$ 291 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Polymixin market. Polymixin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and sup......
  • Global Sepsis Partnering Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The Sepsis Partnering market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sepsis Partnering market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape......
  • Global Cephalosporin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 156
    According to our LPI (LP Information) latest study, the global Cephalosporin market size was valued at US$ 1350.7 million in 2023. With growing demand in downstream market, the Cephalosporin is forecast to a readjusted size of US$ 1319.6 million by 2030 with a CAGR of -0.3% during review period. The research report highlights the growth potential of the global Cephalosporin market. Cephalosporin are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Amoxicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 127
    According to our LPI (LP Information) latest study, the global Amoxicillin market size was valued at US$ 4512.7 million in 2023. With growing demand in downstream market, the Amoxicillin is forecast to a readjusted size of US$ 5711.7 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Amoxicillin market. Amoxicillin are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Metronidazole Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 136
    According to our LPI (LP Information) latest study, the global Metronidazole market size was valued at US$ 110.5 million in 2023. With growing demand in downstream market, the Metronidazole is forecast to a readjusted size of US$ 106.6 million by 2030 with a CAGR of -0.5% during review period. The research report highlights the growth potential of the global Metronidazole market. Metronidazole are expected to show stable growth in the future market. However, product differentiation, redu......
  • Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Drugs for Herpes Labialis (Oral Herpes) market size was valued at US$ 2404.5 million in 2023. With growing demand in downstream market, the Drugs for Herpes Labialis (Oral Herpes) is forecast to a readjusted size of US$ 3402.2 million by 2030 with a CAGR of 5.1% during review period. The research report highlights the growth potential of the global Drugs for Herpes Labialis (Oral Herpes) market. Drugs for Herpes Labialis (Ora......
  • Global Ampicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Ampicillin market size was valued at US$ 161.6 million in 2023. With growing demand in downstream market, the Ampicillin is forecast to a readjusted size of US$ 194.7 million by 2030 with a CAGR of 2.7% during review period. The research report highlights the growth potential of the global Ampicillin market. Ampicillin are expected to show stable growth in the future market. However, product differentiation, reducing costs, a......
  • Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Acinetobacter Infections Treatment market size was valued at US$ million in 2023. With growing demand in downstream market, the Acinetobacter Infections Treatment is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Acinetobacter Infections Treatment market. Acinetobacter Infections Treatment are expected to show stable ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs